Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human phase I trial of ADXS 11001 in patients with advanced, metastatic cervical cancer who have failed first line therapy.

Trial Profile

A first-in-human phase I trial of ADXS 11001 in patients with advanced, metastatic cervical cancer who have failed first line therapy.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jul 2010

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axalimogene filolisbac (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Advaxis
  • Most Recent Events

    • 29 Jul 2010 Ongoing follow-up of surviving patients has shown that the patients who were alive in March are still alive, 3.5 and 3.9 years after initial dosing, according to an Advaxis media release.
    • 23 Mar 2010 Ongoing follow up of surviving patients has shown that two of 15 treated patients are still alive 1,248 and 1,128 days after initial dosing, according to an Advaxis media release.
    • 29 Dec 2009 Updated survival results reported in an Advaxis media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top